Reference entry

HGH Fragment 176-191 (HGH Frag)

Growth Hormone Fragment · Fat Loss Peptide

Overview

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.

Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis.

Reduces new fat synthesis and storage, complementing the lipolytic action for overall fat reduction.

Promotes selective fat loss while preserving lean mass, particularly effective when combined with a caloric deficit and exercise.

Mechanism

Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis.

Research areas

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.
Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.
Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis.
Reduces new fat synthesis and storage, complementing the lipolytic action for overall fat reduction.
Promotes selective fat loss while preserving lean mass, particularly effective when combined with a caloric deficit and exercise.

Research notes

Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Severe injection site reactions or signs of infection
Hypoglycemia symptoms if combined with insulin (dizziness, sweating, confusion)
Allergic reactions (rare)
Any persistent or concerning symptoms
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid

References

FAQs

Is HGH Fragment 176-191 safe to use with insulin?

HGH Frag 176-191 does not affect blood glucose or insulin sensitivity directly, unlike full-length HGH. However, you should still monitor blood glucose if combining with insulin due to the fragment's lipolytic effects and the potential for unpredictable metabolic changes.

Can I combine HGH Fragment 176-191 with full-length HGH?

Not recommended. HGH already contains the 176-191 sequence, so adding the fragment provides redundant lipolytic action while increasing HGH-related side effects without proportional fat-loss benefit. Choose one or the other.

How quickly will I see fat loss from HGH Fragment 176-191?

Fat loss typically becomes noticeable around week 3-4 with proper diet and exercise. Weeks 5-8 show more significant reduction. Most users run 8-12 week cycles, with continued benefits observable through week 12.

Do I need to fast before injecting HGH Fragment 176-191?

Yes. Fasting is important for optimal effect. Inject on an empty stomach and wait at least 30 minutes before eating. Elevated insulin from food intake can suppress the lipolytic signaling that makes this fragment effective.